Mikhail Blagosklonny is a professor of Oncology at the Roswell Park Cancer Institute in New York and a scientist who researches on aging and cancer. He is a holder of a Master’s Degree from the First Pavlov State Medical University, St. Petersburg, in internal medicine and a Ph.D. in cardiology and experimental medicine.
In 2002, he was appointed an associate professor of medicine at New York Medical College, Valhalla, New York. After the appointment, he took the position of senior scientist at Ordway Research Institute in Albany, New York. He remained in the position till 2009 when he was chosen as the professor of oncology at Roswell Park Cancer Institute. Mikhail’s study areas of interest include targeted cancer therapies, which defend healthy cells from damage, as well as the underlying mechanism of aging and anti-aging drugs. Read more on Impact Journals.
Mikhail Blagosklonny’s Hypothesis on the Role of TOR
Mikhail Blagosklonny has come up with a theory on the possible role of TOR signaling in aging and cancer and proposed using rapamycin. Rapamycin is a popular cancer drug that acts as a possible treatment for life extension. Mikhail is seen as one of the most passionate promoters of rapamycin in longevity research.
Mikhail Blagosklonny’s Role at Roswell Park Cancer Institute
Mikhail Blagosklonny joined the Department of Cell Stress Biology at Roswell Park Cancer Institute as an Associate Member and Associate Professor of Oncology. His study program is focused on several aspects of drug resistance as well as the molecular biology of melanoma and several blood malignancies including:
- Clarification of molecular mechanisms underlying oncogene.
- The unearthing of novel prognostic markers of melanoma.
- Understanding the mechanisms through which oxidative stress promotes oncogene.
- Why melanoma cells Gain invasive phenotypes.
- The role of Kruppelr-like transcription factors in the regulation of therapeutic outcomes.
Dr. Blagosklonny’s laboratory is also enthusiastically trailing the development of a novel class of small molecule inhibitors of C-MYC. C-MYC is an oncogenic transcription factor that transcribes more genetic product of 80% of human cancers. His study is aided by the American Cancer Society and National Cancer Institute.
Mikhail is the Chief Editor of Oncotarget, Cell cycle, and Aging. Also, he is an associate editor of therapy and Cancer Biology and is on the editorial board of Cell Differentiation and Death.
View Mikhail’s profile on Loop